UCSF Molecular and Cellular Characterization Laboratory (Breast)

Dr. Esserman and team seek to develop better biologic discriminators of IDLE (indolent lesions of epithelial origin), ultralow, low and interval breast cancers (usually highly proliferative hormone receptor (HR)- positive and negative and/or HER2 positive tumors). Their overall approach, which is made possible by their network of international collaborators and unique data sets, is to retrospectively optimize and prospectively validate new and emergent molecular, morphometric and tumor immune microenvironment assays and to prospectively add the context of germline predisposition.